KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in Net LoansDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Omega Healthcare Investors (OHI) Gains from Sales and Divestitures (2018 - 2025)

Omega Healthcare Investors' Gains from Sales and Divestitures history spans 11 years, with the latest figure at $1.6 million for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 540.05% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $1.6 million, up 540.05%, while the annual FY2025 figure was $1.6 million, 540.05% up from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $1.6 million at Omega Healthcare Investors, up from $251457.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.6 million in Q4 2025 and bottomed at $148538.0 in Q4 2021.
  • The 5-year median for Gains from Sales and Divestitures is $251457.0 (2024), against an average of $531486.4.
  • The largest annual shift saw Gains from Sales and Divestitures plummeted 47.91% in 2024 before it skyrocketed 540.05% in 2025.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $148538.0 in 2021, then rose by 11.22% to $165206.0 in 2022, then skyrocketed by 192.22% to $482772.0 in 2023, then tumbled by 47.91% to $251457.0 in 2024, then surged by 540.05% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for OHI's Gains from Sales and Divestitures are $1.6 million (Q4 2025), $251457.0 (Q4 2024), and $482772.0 (Q4 2023).